Want to see HK:6118 full AI Analyst Report?
Austar Lifesciences Ltd. (6118) Ratios
Austar Lifesciences Ltd. Ratios
HK:6118's free cash flow for Q2 2026 was $66.51M. For the 2026 fiscal year, HK:6118's free cash flow was decreased by $-21.80M and operating cash flow was $88.31M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.36 | 1.31 | 1.34 | 1.32 | 1.46 |
| Quick Ratio | 1.12 | 1.10 | 1.13 | 1.04 | 1.09 |
| Cash Ratio | 0.23 | 0.14 | 0.14 | 0.10 | 0.17 |
| Solvency Ratio | 0.06 | 0.04 | -0.05 | 0.08 | 0.23 |
| Operating Cash Flow Ratio | 0.11 | 0.08 | -0.05 | -0.03 | -0.09 |
| Short-Term Operating Cash Flow Coverage | 0.50 | 0.30 | -0.20 | -0.17 | -1.84 |
| Net Current Asset Value | $ 309.92M | $ 261.59M | $ 190.32M | $ 295.82M | $ 406.88M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.16 | 0.19 | 0.23 | 0.14 | 0.08 |
| Debt-to-Equity Ratio | 0.42 | 0.51 | 0.64 | 0.38 | 0.20 |
| Debt-to-Capital Ratio | 0.29 | 0.34 | 0.39 | 0.27 | 0.16 |
| Long-Term Debt-to-Capital Ratio | 0.07 | 0.03 | 0.13 | 0.04 | 0.06 |
| Financial Leverage Ratio | 2.59 | 2.63 | 2.79 | 2.66 | 2.60 |
| Debt Service Coverage Ratio | 0.29 | 0.18 | 0.07 | 0.62 | 1.39 |
| Interest Coverage Ratio | 4.59 | 2.05 | -2.15 | 12.13 | 70.86 |
| Debt to Market Cap | 0.80 | 1.29 | 0.59 | 0.28 | 0.02 |
| Interest Debt Per Share | 0.69 | 0.82 | 0.99 | 0.68 | 0.31 |
| Net Debt to EBITDA | 0.73 | 3.33 | 13.22 | 1.27 | -0.33 |
| Profitability Margins | |||||
| Gross Profit Margin | 19.16% | 20.08% | 19.05% | 22.66% | 23.77% |
| EBIT Margin | 2.82% | 2.32% | -1.16% | 5.69% | 5.80% |
| EBITDA Margin | 6.03% | 4.71% | 1.43% | 7.41% | 6.48% |
| Operating Profit Margin | 3.54% | 2.34% | -1.70% | 5.40% | 15.48% |
| Pretax Profit Margin | 3.14% | 1.41% | -1.95% | 5.54% | 15.84% |
| Net Profit Margin | 2.21% | 1.07% | -6.43% | 4.05% | 13.76% |
| Continuous Operations Profit Margin | 2.15% | 0.90% | -1.97% | 4.67% | 13.53% |
| Net Income Per EBT | 70.24% | 75.94% | 329.77% | 73.17% | 86.87% |
| EBT Per EBIT | 88.87% | 60.18% | 114.72% | 102.72% | 102.34% |
| Return on Assets (ROA) | 1.59% | 0.77% | -5.26% | 3.66% | 13.56% |
| Return on Equity (ROE) | 4.11% | 2.03% | -14.68% | 9.75% | 35.25% |
| Return on Capital Employed (ROCE) | 5.76% | 3.93% | -3.06% | 11.31% | 34.33% |
| Return on Invested Capital (ROIC) | 3.06% | 1.82% | -2.28% | 7.84% | 27.58% |
| Return on Tangible Assets | 1.62% | 0.79% | -5.36% | 3.75% | 13.70% |
| Earnings Yield | 8.44% | 5.86% | -15.60% | 9.57% | 4.41% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.56 | 1.48 | 1.77 | 2.16 | 2.99 |
| Payables Turnover | 2.69 | 3.14 | 3.52 | 4.14 | 4.36 |
| Inventory Turnover | 4.42 | 5.03 | 5.87 | 4.55 | 3.63 |
| Fixed Asset Turnover | 3.89 | 3.62 | 4.62 | 4.97 | 6.46 |
| Asset Turnover | 0.72 | 0.72 | 0.82 | 0.90 | 0.99 |
| Working Capital Turnover Ratio | 3.88 | 3.95 | 4.21 | 4.46 | 4.97 |
| Cash Conversion Cycle | 180.42 | 202.97 | 164.24 | 161.42 | 138.73 |
| Days of Sales Outstanding | 233.75 | 246.70 | 205.85 | 169.30 | 121.88 |
| Days of Inventory Outstanding | 82.53 | 72.57 | 62.17 | 80.22 | 100.58 |
| Days of Payables Outstanding | 135.85 | 116.30 | 103.78 | 88.09 | 83.73 |
| Operating Cycle | 316.27 | 319.27 | 268.01 | 249.51 | 222.45 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.25 | 0.19 | -0.12 | -0.07 | -0.20 |
| Free Cash Flow Per Share | 0.19 | 0.15 | -0.26 | -0.30 | -0.40 |
| Dividend Paid and CapEx Coverage Ratio | 4.50 | 4.82 | -0.88 | -0.32 | -1.03 |
| Capital Expenditure Coverage Ratio | 4.50 | 4.82 | -0.88 | -0.32 | -1.03 |
| Operating Cash Flow Coverage Ratio | 0.37 | 0.25 | -0.13 | -0.11 | -0.67 |
| Operating Cash Flow to Sales Ratio | 0.08 | 0.07 | -0.04 | -0.02 | -0.05 |
| Free Cash Flow Yield | 24.90% | 28.54% | -18.37% | -16.98% | -3.24% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 11.84 | 17.07 | -6.41 | 10.45 | 22.70 |
| Price-to-Sales (P/S) Ratio | 0.26 | 0.18 | 0.41 | 0.42 | 3.12 |
| Price-to-Book (P/B) Ratio | 0.49 | 0.35 | 0.94 | 1.02 | 8.00 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 4.02 | 3.50 | -5.44 | -5.89 | -30.85 |
| Price-to-Operating Cash Flow Ratio | 3.12 | 2.78 | -11.61 | -24.11 | -60.85 |
| Price-to-Earnings Growth (PEG) Ratio | 0.11 | -0.15 | 0.03 | -0.15 | 0.03 |
| Enterprise Value Multiple | 5.07 | 7.21 | 42.13 | 6.99 | 47.86 |
| Enterprise Value | 467.78M | 509.56M | 1.06B | 1.12B | 6.25B |
| EV to EBITDA | 5.07 | 7.21 | 42.13 | 6.99 | 47.86 |
| EV to Sales | 0.31 | 0.34 | 0.60 | 0.52 | 3.10 |
| EV to Free Cash Flow | 4.69 | 6.51 | -7.93 | -7.20 | -30.64 |
| EV to Operating Cash Flow | 3.65 | 5.16 | -16.91 | -29.46 | -60.43 |
| Tangible Book Value Per Share | 1.53 | 1.47 | 1.42 | 1.61 | 1.50 |
| Shareholders’ Equity Per Share | 1.61 | 1.54 | 1.50 | 1.75 | 1.53 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.32 | 0.36 | -0.01 | 0.16 | 0.15 |
| Revenue Per Share | 2.99 | 2.93 | 3.43 | 4.21 | 3.93 |
| Net Income Per Share | 0.07 | 0.03 | -0.22 | 0.17 | 0.54 |
| Tax Burden | 0.70 | 0.76 | 3.30 | 0.73 | 0.87 |
| Interest Burden | 1.12 | 0.61 | 1.68 | 0.97 | 2.73 |
| Research & Development to Revenue | 0.03 | 0.04 | 0.03 | 0.03 | 0.03 |
| SG&A to Revenue | 0.15 | 0.16 | 0.08 | 0.06 | 0.06 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 3.89 | 6.14 | 1.82 | -0.43 | -0.37 |
Currency in CNY
